Latest Benzimidazoles Stories
RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that PradaxaÂ® (dabigatran etexilate mesylate) capsules has been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals, as ranked by U.S.
RIDGEFIELD, Conn., May 19, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
In an evaluation of contemporary antireflux therapies for chronic gastroesophageal reflux disease (GERD), most patients who received treatment with either the proton pump inhibitor esomeprazole or laparoscopic antireflux surgery achieved and remained in disease remission for 5 years.
HOUSTON, April 19, 2011 /PRNewswire/ -- An Ohio woman suffered bone deterioration and broken bones because of hidden risks with pharmaceutical giant AstraZeneca's acid reflux drug Nexium, The Gibson Law Firm alleges in a lawsuit filed today in Texas federal court. Filed in the U.S.
NEW ORLEANS, April 5, 2011 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. (Takeda) announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate).
CHAPEL HILL, N.C., Feb. 14, 2011 /PRNewswire/ -- Thought Leader Select, a Research Triangle, NC firm focused on collaborations between the biopharmaceutical industry and the medical community, announces the launch of a new media partnership with biopharmaceutical industry blog Marketing4Health.
RADNOR, Pa., Jan. 19, 2011 /PRNewswire/ -- HTH Worldwide, a global health and safety services company, today announced the expansion of its mobile and online brand name medication translation guide for world travelers.
RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LYÂ® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan.
Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed.
The recent approval of a drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm.
- The act of sweetening by admixture of some saccharine substance.